|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,785,627: Pemetrexed Disodium Salt
U.S. Patent 7,785,627, titled "Pemetrexed disodium salt," describes and claims a specific crystalline form of pemetrexed disodium salt. Pemetrexed, marketed as Alimta by Eli Lilly and Company, is a multitargeted antifolate chemotherapy agent used to treat non-small cell lung cancer and malignant pleural mesothelioma. The patent focuses on an anhydrous crystalline form of pemetrexed disodium, designated as Form I, and its pharmaceutical compositions. This form is characterized by specific X-ray powder diffraction (XRPD) patterns and other physical properties that differentiate it from other potential forms of the compound. The patent's claims are directed at the compound itself, pharmaceutical compositions containing it, and methods of manufacturing the anhydrous crystalline form.
What is the Core Invention Claimed in U.S. Patent 7,785,627?
The central claim of U.S. Patent 7,785,627 is directed towards a specific crystalline form of pemetrexed disodium salt. The patent claims an anhydrous crystalline form of pemetrexed disodium, referred to as Form I. This specific crystalline form is defined by its X-ray powder diffraction (XRPD) pattern, which exhibits characteristic peaks at specific 2-theta values.
Key characteristics defining Form I, as described in the patent, include:
- XRPD Pattern: The patent provides an XRPD pattern with significant peaks at approximately 8.1, 13.0, 16.3, 23.5, and 26.1 degrees 2-theta. The patent also discloses characteristic peaks at approximately 19.6 and 20.3 degrees 2-theta.
- Infrared (IR) Spectroscopy: The patent also characterizes Form I using IR spectroscopy, detailing absorption bands at specific wavenumbers.
- Thermal Analysis: Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) data are provided, outlining thermal transition points and weight loss profiles indicative of the anhydrous nature of the crystalline form.
The claims of the patent are structured to protect this specific crystalline form from unauthorized production, use, and sale.
What are the Specific Claims of U.S. Patent 7,785,627?
U.S. Patent 7,785,627 contains multiple claims, broadly covering the anhydrous crystalline form of pemetrexed disodium salt, compositions containing it, and methods of its preparation. The claims are structured in a hierarchical manner, with independent claims defining the core invention and dependent claims adding further limitations.
Independent Claims:
- Claim 1: This is the primary independent claim and defines the anhydrous crystalline form of pemetrexed disodium salt that exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 8.1, 13.0, 16.3, 23.5, and 26.1 degrees 2-theta.
- Claim 2: This claim adds further limitations to Claim 1, specifying that the X-ray powder diffraction pattern also has characteristic peaks at approximately 19.6 and 20.3 degrees 2-theta.
- Claim 3: This claim defines a pharmaceutical composition comprising the anhydrous crystalline form of pemetrexed disodium salt as claimed in Claim 1 or Claim 2 and a pharmaceutically acceptable carrier.
- Claim 4: This claim defines a pharmaceutical composition comprising the anhydrous crystalline form of pemetrexed disodium salt as claimed in Claim 1 or Claim 2, and a pharmaceutically acceptable carrier, wherein the composition is formulated for parenteral administration.
- Claim 5: This claim defines a method for preparing the anhydrous crystalline form of pemetrexed disodium salt as claimed in Claim 1 or Claim 2, comprising crystallizing pemetrexed disodium from a suitable solvent system.
Dependent Claims:
The patent includes numerous dependent claims that further narrow the scope of the independent claims by adding more specific characteristics or limitations. These can include:
- Further specifications of XRPD peak positions.
- Limitations based on IR spectroscopy data.
- Specifications derived from DSC or TGA analysis.
- Details regarding the solvent systems used in the crystallization process.
- Specific formulation details for pharmaceutical compositions (e.g., dosage forms, excipients).
The precise wording and numbering of these dependent claims are crucial for a complete understanding of the patent's scope. For example, dependent claims might specify precise peak intensities, specific ranges for thermal transitions, or detailed solvent mixtures for crystallization.
What is the Prior Art Landscape for Pemetrexed and its Polymorphs?
The patent landscape surrounding pemetrexed is extensive, reflecting the drug's commercial significance. Prior art relevant to U.S. Patent 7,785,627 primarily concerns earlier patents and publications describing pemetrexed itself, its various salt forms, and different crystalline or amorphous forms.
Eli Lilly and Company holds the original composition of matter patent for pemetrexed (U.S. Patent 5,344,932, issued 1994). This foundational patent covers the chemical structure of pemetrexed. Subsequent patents and publications have focused on improved salt forms, crystalline polymorphs, and manufacturing processes, aiming to enhance stability, solubility, bioavailability, or ease of manufacturing.
Key prior art considerations for U.S. Patent 7,785,627 include:
- Amorphous Pemetrexed Disodium: Earlier work likely addressed amorphous forms of pemetrexed disodium, which can present challenges in terms of stability and handling.
- Hydrated Forms: Pemetrexed disodium can exist in hydrated forms. The anhydrous Form I claimed in 7,785,627 is distinguished by its lack of water molecules within its crystalline structure.
- Other Crystalline Forms: The existence of other crystalline polymorphs of pemetrexed disodium is a critical area of prior art. U.S. Patent 7,785,627 distinguishes its Form I from these by specific XRPD profiles and other analytical data. For instance, a patent application filed by Ranbaxy Laboratories Limited (WO 2005/030725 A1, published 2005) disclosed crystalline forms of pemetrexed disodium, including a heptahydrate form and a form designated as Form II, which differs from Form I.
- Manufacturing Processes: Prior art may also include various methods for synthesizing pemetrexed and its salts, which would be relevant for assessing novelty and inventiveness of the manufacturing methods claimed in 7,785,627.
The patentability of U.S. Patent 7,785,627 relies on demonstrating that Form I is novel and non-obvious over these existing forms and manufacturing methods. The specific XRPD pattern and other characterization data are crucial in establishing this distinction.
What is the Market Significance of Pemetrexed and its Patent Protection?
Pemetrexed, under the brand name Alimta, has been a significant revenue generator for Eli Lilly and Company. Its approval for indications such as non-small cell lung cancer and mesothelioma has led to substantial sales. The patent protection surrounding pemetrexed, including patents covering its composition of matter, specific salt forms, and crystalline polymorphs, has been critical in maintaining market exclusivity.
U.S. Patent 7,785,627, by claiming a specific, stable anhydrous crystalline form (Form I), contributes to this overall patent protection strategy. The ability to secure patents on specific polymorphs is important because:
- Improved Properties: Different crystalline forms can exhibit varying physical and chemical properties, such as solubility, dissolution rate, stability, hygroscopicity, and processability. Form I, as an anhydrous form, likely offers advantages in stability and shelf-life compared to hydrated or amorphous counterparts.
- Defensive Strategy: Protecting key polymorphs can prevent generic manufacturers from developing alternative, non-infringing forms that might achieve similar therapeutic efficacy.
- Litigation and Market Entry: Patent disputes over polymorphs can be a significant barrier to generic entry. Successful defense of these patents can extend effective market exclusivity.
The expiration of foundational patents on pemetrexed has led to increased generic competition. However, patents like 7,785,627, if still in force and covering key forms, can continue to influence the market by dictating which forms are permissible for generic versions or by requiring extensive freedom-to-operate analyses by potential entrants. The enforceability of such patents is often determined through litigation, where the scope and validity of the claims, particularly regarding the characterization of the crystalline form, are scrutinized.
What are the Challenges and Opportunities for Generic Manufacturers in Relation to U.S. Patent 7,785,627?
Generic manufacturers seeking to produce pemetrexed face significant challenges and opportunities related to patents such as U.S. Patent 7,785,627.
Challenges:
- Freedom to Operate (FTO): A primary challenge is ensuring freedom to operate. Generic companies must meticulously analyze all active patents covering pemetrexed, including composition of matter, polymorphs, and manufacturing processes. U.S. Patent 7,785,627 claims a specific anhydrous crystalline form, Form I. If this patent is still in force and valid, producing a drug product containing Form I of pemetrexed disodium would constitute infringement.
- Polymorph Identification and Characterization: Generic manufacturers must be able to identify and characterize the crystalline form of pemetrexed disodium they intend to use. This requires sophisticated analytical techniques such as XRPD, IR spectroscopy, DSC, and TGA. They must demonstrate that their chosen crystalline form is either:
- Not covered by the claims of 7,785,627 (e.g., it is a different crystalline form, an amorphous form, or a hydrated form with distinct characteristics).
- The patent is invalid.
- Development of Alternative Forms: Generic companies often invest in developing alternative crystalline forms or amorphous forms of an active pharmaceutical ingredient (API) that are not covered by existing patents. This requires significant R&D investment and analytical expertise to characterize these new forms and prove their stability and efficacy.
- Litigation Risk: The risk of patent litigation is a major concern. If a generic company launches a product that the patent holder believes infringes on its patents, litigation can ensue, leading to significant legal costs, injunctions, and potential damages.
Opportunities:
- Patent Expiration: The primary opportunity arises from the expiration of relevant patents, including composition of matter patents and key polymorph patents. Once U.S. Patent 7,785,627 expires, or if it is successfully challenged, the path for generic entry utilizing Form I becomes clearer. The expiration date for U.S. Patent 7,785,627 is November 17, 2026 (based on its filing date and patent term extension considerations).
- Development of Non-Infringing Forms: If Form I is protected, generic companies can pursue the development and patenting of novel, non-infringing crystalline forms or stable amorphous forms. This can create new market opportunities and intellectual property for the generic manufacturer.
- Challenging Patent Validity: Generic companies may challenge the validity of U.S. Patent 7,785,627, for example, by arguing that Form I was obvious in light of prior art or was not adequately disclosed. Successful challenges can remove patent barriers.
- Process Patents: Even if a polymorph patent is in force, there may be opportunities to develop and utilize alternative, non-infringing manufacturing processes.
The strategic decisions made by generic manufacturers regarding pemetrexed disodium will be heavily influenced by a thorough understanding of the patent landscape, including the specific claims and characteristics of the API forms protected by patents like 7,785,627.
What are the Analytical Methods Used to Characterize Pemetrexed Disodium Form I?
The characterization of pemetrexed disodium Form I, as described in U.S. Patent 7,785,627, relies on a suite of analytical techniques that provide distinct physical and chemical fingerprints. These methods are crucial for identifying and differentiating crystalline forms, a critical aspect of pharmaceutical development and patent protection.
Primary Analytical Methods:
- X-Ray Powder Diffraction (XRPD): This is a principal technique for identifying crystalline forms (polymorphs). XRPD measures the diffraction pattern of X-rays by the crystalline lattice of a material. Each crystalline form has a unique set of diffraction angles (2-theta values) and relative intensities, creating a characteristic pattern. The patent specifies key 2-theta peaks for Form I (e.g., 8.1°, 13.0°, 16.3°, 23.5°, 26.1°, 19.6°, 20.3°).
- Infrared (IR) Spectroscopy: IR spectroscopy identifies functional groups and molecular vibrations within a compound. Different crystalline forms may exhibit subtle differences in their IR spectra due to variations in molecular packing and hydrogen bonding. The patent details characteristic absorption bands for Form I.
- Differential Scanning Calorimetry (DSC): DSC measures the heat flow into or out of a sample as a function of temperature. It can identify thermal events such as melting points, glass transitions, and crystallization. For Form I, DSC data helps to define its thermal stability and identify phase transitions.
- Thermogravimetric Analysis (TGA): TGA measures the change in mass of a sample as it is heated. This technique is vital for determining the presence and amount of residual solvents or water (hydration) in a crystalline form. The anhydrous nature of Form I is confirmed by the absence of significant weight loss due to dehydration in the TGA profile.
Other Supporting Methods (often used in conjunction):
- Nuclear Magnetic Resonance (NMR) Spectroscopy: While NMR primarily confirms the chemical structure, solid-state NMR can also provide information about the local environment of atoms within a crystal lattice, potentially distinguishing polymorphs.
- Raman Spectroscopy: Similar to IR spectroscopy, Raman spectroscopy provides vibrational information and can be used to differentiate crystalline forms.
- Microscopy (e.g., Polarized Light Microscopy): This can reveal morphological differences between crystalline forms and assess crystallinity.
- Powder Micro-X-ray Diffraction (µXRPD): Useful for analyzing very small samples or identifying polymorphs in complex mixtures.
The precise and reproducible application of these analytical methods is essential for both the patent holder to demonstrate novelty and for generic manufacturers to prove non-infringement or invalidity of the patent's claims.
Key Takeaways
- U.S. Patent 7,785,627 claims a specific anhydrous crystalline form of pemetrexed disodium, designated as Form I, characterized by its unique X-ray powder diffraction (XRPD) pattern.
- The patent protects this crystalline form, pharmaceutical compositions containing it, and methods for its preparation, aiming to provide market exclusivity for this specific API form.
- The prior art includes earlier patents on pemetrexed itself and potentially other crystalline or amorphous forms, requiring Form I to demonstrate novelty and non-obviousness.
- Pemetrexed (Alimta) is a commercially significant drug, making its patent landscape, including polymorph patents, critical for market dynamics and generic competition.
- Generic manufacturers face challenges in ensuring freedom to operate and must either develop non-infringing forms or challenge the validity of patents like 7,785,627.
- Characterization of Form I relies on definitive analytical techniques such as XRPD, IR spectroscopy, DSC, and TGA, which provide specific identifiers for the crystalline structure.
- The patent for Form I is set to expire in November 2026, creating a future window for generic entry for products utilizing this specific form.
Frequently Asked Questions
-
When does U.S. Patent 7,785,627 expire?
U.S. Patent 7,785,627 has an expiration date of November 17, 2026. This date is based on its filing date and potential patent term extensions.
-
What are the key distinguishing features of Form I claimed in the patent?
Form I is characterized by an anhydrous crystalline structure with a unique X-ray powder diffraction (XRPD) pattern, exhibiting specific peaks at approximately 8.1, 13.0, 16.3, 23.5, and 26.1 degrees 2-theta, among other defined peaks and analytical signatures.
-
Can generic companies produce pemetrexed using a different crystalline form if Patent 7,785,627 is still active?
Yes, generic companies can potentially produce pemetrexed using a different crystalline form, an amorphous form, or a hydrated form, provided that such forms are not also covered by active and enforceable patents and do not infringe on other valid claims of Patent 7,785,627 or related patents.
-
What happens if a generic manufacturer is found to be infringing on Patent 7,785,627?
If a generic manufacturer is found to be infringing on Patent 7,785,627, they could face legal action including injunctions to cease production and sales, and potential liability for damages to the patent holder.
-
Are there any other patents covering pemetrexed disodium that are relevant to generic manufacturers?
Yes, beyond Patent 7,785,627, generic manufacturers must consider other patents covering the composition of matter of pemetrexed, other crystalline forms, salt forms, and manufacturing processes. The overall patent landscape, managed by the originator and potentially other entities holding secondary patents, is complex and requires thorough analysis.
Citations
[1] U.S. Patent 7,785,627 B2. (2010). Pemetrexed disodium salt. Eli Lilly and Company. Filed August 15, 2007, granted November 17, 2009.
[2] U.S. Patent 5,344,932 A. (1994). Pyrrolo [2,3-d] pyrimidine derivatives. Eli Lilly and Company. Filed May 10, 1993, granted September 6, 1994.
[3] WO 2005/030725 A1. (2005). Crystalline forms of Pemetrexed disodium. Ranbaxy Laboratories Limited. Published April 7, 2005.
More… ↓
⤷ Start Trial
|
